Ash A. Alizadeh, MD/PhD
Moghadam Family Professor
Medicine - Oncology

CLINICAL OFFICES
- Stanford Comprehensive Cancer Center
  875 Blake Wilbur Dr
  MC 6560
  Stanford, CA 94305
  Tel (650) 498-6000  Fax (650) 724-5203

ACADEMIC CONTACT INFORMATION
- Alternate Contact
  Administrative Assistant
  Tel 650.723.5290

Bio

CLINICAL FOCUS
- Cancer > Lymphoma
- Lymphoma
- B-Cell Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Burkitt Lymphoma
- Follicular Lymphoma
- Diffuse Large-Cell Lymphomas
- Leukemia, Hairy Cell
- Lymphoma, B-Cell, Marginal Zone
- Hodgkin Disease
- Medical Oncology

ACADEMIC APPOINTMENTS
- Professor, Medicine - Oncology
- Member, Bio-X
- Member, Institute for Stem Cell Biology and Regenerative Medicine
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS
- Chair, Seminar Committee, Stanford Immunology Program, (2011- present)
- Admissions Panel, Medical Scientist Training Program, Stanford University, (2011- present)
• Admissions Panel, Stanford Medical School, (2012- present)
• Steering Committee Member & Mentor, Stanford Computational & Systems Immunology, (2012- present)

HONORS AND AWARDS
• Magna cum laude, College & Departmental Honors, UCLA (6/1993)
• NIH Research Fellow Award, NIH/NCI (6/1995)
• Research Scholar Award, HHMI-NIH (1996 # 1998)
• Intramural Research Award, NIH/NCI (1997 # 1998)
• Research Scholar Award for Outstanding Research, HHMI (1998)
• Medical Scientist Training Program Award, NIH (1996-2003)
• Sandler Fellow Award, UCSF (2003-2004)
• Franklin G. Ebaugh, Jr. Award for Outstanding Research, Dept of Medicine, Stanford (2004-2005)
• Leukemia & Lymphoma Society Special Fellow in Clinical Research, Stanford University (2010-2013)
• American Society for Clinical Oncology Career Development Award, Stanford University (2010-2013)
• Clinical Investigator Program: Fellow Award, Stanford University Medical Center (2004-2010)
• Josephine Q. Berry Faculty Scholar in Cancer Research, Stanford University (2010)
• Bent & Janet Cardan Oncology Research Fellow, Stanford University (2010)
• Gabrielle’s Angel Foundation, Stanford University (2012-2015)
• Doris Duke Clinical Scientist Development Award, Stanford University (2011)
• Cancer Innovation Award, Stanford Hospital & Clinics (2012-2013)
• Damon Runyon Cancer Research Foundation Clinical Investigator Award, Stanford University (2014-2017)
• V-Foundation Scholar/Martin D Abeloff Award (1st Place), Stanford University (2014-2016)
• Celgene Young Investigator Award, Stanford University (2014-2015)
• American Society of Hematology Scholar Award, Stanford University (2015-2017)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS
• Vice Chair, Committee on Epigenetics and Genomics, American Society of Hematology (2014 - present)
• Mentor, Lymphoma Clinical Research Mentoring Program, Lymphoma Research Foundation (2013 - present)
• Leader, Scientific Program Committee on Lymphoma, Myeloma, Plasma Cell Disorders, American Society of Clinical Oncology (2011 - 2014)

PROFESSIONAL EDUCATION
• Board Certification: Medical Oncology, American Board of Internal Medicine (2009)
• Medical Education: Stanford University School of Medicine (2003) CA
• Fellowship: Stanford University Hematology and Oncology Fellowship (2009) CA
• Residency: Stanford University Internal Medicine Residency (2006) CA
• Internship: Stanford University Internal Medicine Residency (2004) CA
• MD, Stanford university School of Medicine , Medicine (2003)
• PhD, Stanford university School of Medicine , Biophysics/Dept of Biochemistry (2003)
• B.S., UCLA , Biochemistry (1994)

LINKS
• Alizadeh Lab: http://med.stanford.edu/labs/ash_alizadeh/
Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My group's research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies.

My group develops and applies genomic biomarkers of tumor cells, whether detected through biopsy of the primary neoplasm, or noninvasively through monitoring of the bodily fluids including blood. We apply such genomic biomarkers for the early detection, diagnosis, and monitoring of diverse tumors including lymphomas and solid tumors.

We are also interested in better molecular understanding of normal tissue stem cells and their malignant tumor-initiating counterparts (cancer stem cells), toward identification of the underlying mechanisms relevant to specific cancers of the hematopoietic system. These tumors include follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma.

We have also worked to build prognostic and predictive models for clinical and therapeutic outcomes of diverse human malignancies, through large-scale bioinformatic meta-analysis of human tumor transcriptomes, including deconvolution of complex tumor admixtures including infiltrating leukocytes.

In this effort, we help build and employ tools from functional genomics, computational biology, molecular genetics, and mouse models. We are applying this knowledge toward the design of clinical trials in the treatment of patients with various malignancies, whom I care for directly or indirectly, as a clinician specializing in Medical Oncology and Hematology.

CLINICAL TRIALS

- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease, Recruiting
- A Multi-Center Study of Brutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas, Not Recruiting
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma, Not Recruiting
- A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab, Not Recruiting
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study, Not Recruiting
- Chemoeembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery, Not Recruiting
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
- Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP), Not Recruiting
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer, Not Recruiting
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting
- VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas, Not Recruiting
Teaching

COURSES

2022-23
• Seminar in Immunology: IMMUNOL 311 (Aut, Win, Spr)

2021-22
• Seminar in Immunology: IMMUNOL 311 (Aut, Win, Spr)

2020-21
• Seminar in Immunology: IMMUNOL 311 (Aut, Win, Spr)

2019-20
• Seminar in Immunology: IMMUNOL 311 (Aut, Win, Spr)

STANFORD ADVISEES

Med Scholar Project Advisor
Andrea Garofalo

Postdoctoral Faculty Sponsor
Stefan Alig, Jan Lukas Boegeholz, Jurik Mutter, Cedric Rossi, Takeshi Sugio

Doctoral Dissertation Advisor (AC)
Andrea Garofalo

Doctoral Dissertation Co-Advisor (AC)
Emily Hamilton

Postdoctoral Research Mentor
Stefan Alig, Jan Lukas Boegeholz, Mark Hamilton, Jurik Mutter, Cedric Rossi, Joe Schroers-Martin, Takeshi Sugio, Rui Wang

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

• Biochemistry (Phd Program)
• Biophysics (Phd Program)
• Cancer Biology (Phd Program)
• Immunology (Phd Program)
• Medicine (Masters Program)

Publications

PUBLICATIONS

• Molecular Monitoring of Lymphomas. *Annual review of pathology*
  Schroers-Martin, J. G., Alig, S., Garofalo, A., Tessoulin, B., Sugio, T., Alizadeh, A. A.
  2022

• Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. *Blood*
  de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A. J., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, et al
  2022
• Inferring gene expression from cell-free DNA fragmentation profiles. *Nature biotechnology*
  Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., Soo, J., Schroers-Martin, J. G., Chen, et al
  2022

• Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. *Nature biotechnology*
  Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., Macaulay, C. W., Hamilton, E. G., Chen, et al
  2021

• Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Alig, S. n., Macaulay, C. W., Kurtz, D. M., Dührsen, U. n., Hüttmann, A. n., Schmitz, C. n., Jin, M. C., Sworder, B. J., Garofalo, A. n., Shahrokh Esfahani, M. n., Nabet, B. Y., Soo, J. n., Scherer, et al
  2021: JCO2002573

• The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. *Cancer cell*
  Steen, C. B., Luca, B. A., Esfahani, M. S., Azizi, A., Sworder, B. J., Nabet, B. Y., Kurtz, D. M., Liu, C. L., Khameneh, F., Advani, R. H., Natkunam, Y., Myklebust, J. H., Diehn, et al
  2021

• Atlas of clinically distinct cell states and ecosystems across human solid tumors. *Cell*
  Luca, B. A., Steen, C. B., Matusiak, M., Azizi, A., Varma, S., Zhu, C., Przybyl, J., Espín-Pérez, A., Diehn, M., Alizadeh, A. A., van de Rijn, M., Gentles, A. J., Newman, et al
  2021

• Integrating genomic features for non-invasive early lung cancer detection. *Nature*
  Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Jin, et al
  2020; 580 (7802): 245-251

• Integrating genomic features for non-invasive early lung cancer detection *NATURE*
  Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C., Hui, A. B., Jin, et al
  2020

• Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. *Cell*
  Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al
  2020

• Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. *Cell*
  Kurtz, D. M., Esfahani, M. S., Scherer, F., Soo, J., Jin, M. C., Liu, C. L., Newman, A. M., Dührsen, U., Huttmann, A., Casasnovas, O., Westin, J. R., Ritgen, M., Botcher, et al
  2019

• Determining cell type abundance and expression from bulk tissues with digital cytometry *NATURE BIOTECHNOLOGY*
  Newman, A. M., Steen, C. B., Liu, C., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., Diehn, M., Alizadeh, A. A.
  2019; 37 (7): 773-+}

• Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA *CANCER DISCOVERY*
  Dudley, J. C., Schroers-Martin, J., Lazzareschi, D., Shi, W., Chen, S. B., Esfahani, M. S., Trivedi, D., Chabon, J. J., Chaudhuri, A. A., Stehr, H., Liu, C., Lim, H., Costa, et al
  2019; 9 (4): 500–509

• Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nature biotechnology*
  Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F. n., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D. n., Diehn, M. n., Alizadeh, A. A.
  2019
- Predicting HLA class II antigen presentation through integrated deep learning. *Nature biotechnology*
  Chen, B. n., Khodadoust, M. S., Olsson, N. n., Wagar, L. E., Fast, E. n., Liu, C. L., Muftuoglu, Y. n., Sworder, B. J., Diehn, M. n., Levy, R. n., Davis, M. M., Elias, J. E., Altman, et al
  2019

- Analysis of Urinary Cell-free DNA for Early Detection and Surveillance of Bladder Cancer
  Dudley, J., Schroers-Martin, J., Lazzareschi, D., Shi, W., Chen, S., Liao, J., Alizadeh, A., Diehn, M.
  ELSEVIER SCIENCE INC. 2018: 968

- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma *JOURNAL OF CLINICAL ONCOLOGY*
  Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
  2018; 36 (28): 2845+

- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
  2018: JCO2018785246

- B cell lymphomas present immunoglobulin neoantigens. *Blood*
  Khodadoust, M. S., Olsson, N. n., Chen, B. n., Sworder, B. n., Shree, T. n., Liu, C. L., Zhang, L. n., Czerwinski, D. K., Davis, M. M., Levy, R. n., Elias, J. E., Alizadeh, A. A.
  2018

- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA *SCIENCE TRANSLATIONAL MEDICINE*
  Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al
  2016; 8 (364)

- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients *NATURE COMMUNICATIONS*
  Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al
  2016; 7

- Integrated digital error suppression for improved detection of circulating tumor DNA *NATURE BIOTECHNOLOGY*
  Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., Zhou, L., Carter, J. N., West, et al
  2016; 34 (5): 547-555

- The prognostic landscape of genes and infiltrating immune cells across human cancers *NATURE MEDICINE*
  Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., Diehn, M., West, R. B., Plevritis, et al
  2015; 21 (8): 938-945

- Toward understanding and exploiting tumor heterogeneity *NATURE MEDICINE*
  Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., Esteller, M., Fitzgerald, R., Korbel, et al
  2015; 21 (8): 846-853

- Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. *Blood*
  Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., Visser, B., Callahan, J., Kong, et al
  2015; 125 (24): 3679-3687

- Robust enumeration of cell subsets from tissue expression profiles. *Nature methods*
  Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., Alizadeh, A. A.
  2015; 12 (5): 453-457

- Robust enumeration of cell subsets from tissue expression profiles *NATURE METHODS*
  Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., Alizadeh, A. A.
• Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. *Proceedings of the National Academy of Sciences of the United States of America*
Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., Irish, J., Stehr, H., Vicente-Dueñas, C., Romero-Camarero, I., Sanchez-Garcia, I., Plevritis, S. K., Arber, et al
2015; 112 (10): E1116-25

• FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution *BIOINFORMATICS*
Newman, A. M., Bratman, S. V., Stehr, H., Lee, L. J., Liu, C. L., Diehn, M., Alizadeh, A. A.
2014; 30 (23): 3390-3393

• Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. *Journal of clinical oncology*
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al
2014; 32 (17): 1797-1803

• Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma *NATURE COMMUNICATIONS*
Green, M. R., Vicente-Duenas, C., Romero-Camarero, I., Liu, C. L., Dai, B., Gonzalez-Herrero, I., Garcia-Ramirez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., Campos-Sanchez, E., Orfao, A., Pintado, et al
2014; 5

• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nature medicine*
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al
2014; 20 (5): 548-554

• Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. *Blood*
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., Kela, I., Hopmans, E. S., Myklebust, J. H., Ji, H., Plevritis, S. K., Levy, R., Alizadeh, et al
2013; 121 (9): 1604-1611

• Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma *Cell*
Chao, M. P., Majeti R.
2010; 142 (5): 699-713

• Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma *NEW ENGLAND JOURNAL OF MEDICINE*
Alizadeh, A. A., Gentles, A. J., Lossos, I. S., Levy, R.
2009; 360 (26): 2794-2795

• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling *NATURE*
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. G., Sabet, H., Tran, T., Yu, X., Powell, J. I., Yang, L. M., Marti, et al
2000; 403 (6769): 503-511

• A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. *Blood advances*
Cherr, H. J., Aitig, S., Oki, Y., Nastoupil, I. J., Fayad, L. E., Neelapu, S. S., Turturro, F., Hageemeister, F. B., Craig, A., Macaulay, C., Rodriguez, M. A., Lee, H. J., McDonnell, et al
2022

• Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. *Cancer research*
Nair, V. S., Hui, A. B., Chabon, J. J., Shahrokhi Esfahani, M., Stehr, H., Nabet, B. Y., Zhou, L., Chaudhuri, A. A., Benson, J. A., Ayers, K., Bedi, H., Ramsey, M. C., Van Wert, et al
2022

- Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study. *Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology*
  Yang, L. M., Costales, C., Ramanathan, M., Buttery, P. L., Murugesan, K., Schroers-Martin, J., Alizadeh, A. A., Boyd, S. D., Brown, J. M., Nadeau, K. C., Nadimpalli, S. S., Wang, A. X., Busque, et al
2022; 153: 105217

- Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non-small cell lung cancer.
  Jun, S., Shukla, N., Durm, G., Hui, A. B., Cao, S., Kunder, C., Alizadeh, A. A., Hanna, N. H., Diehn, M.
LIPPINCOTT WILLIAMS & WILKINS. 2022

- Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
  Cherng, H., Alig, S., Oki, Y., Nastoupol, L. J., Fayad, L., Neelapu, S., Turturro, F., Hagemeister, F. B., Rodriguez, M., McDonnell, T., Flowers, C., Vega, F., Green, et al
LIPPINCOTT WILLIAMS & WILKINS. 2022

- Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. *Cancers*
  Yaung, S. J., Woestmann, C., Ju, C., Ma, X. M., Gattam, S., Zhou, Y., Xi, L., Pal, S., Balasubramanayam, A., Tikoo, N., Heussel, C. P., Thomas, M., Kriegsmann, et al
2022; 14 (10)

- CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. *Blood cancer discovery*
  Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbetti, K. S., Gabriel, E., Kurtz, D. M., Khodadoust, M. S., Gupta, et al
2022

- Circulating Tumor DNA in Lymphoma: Principles and Future Directions. *Blood cancer discovery*
  Roschewski, M., Rossi, D., Kurtz, D. M., Alizadeh, A. A., Wilson, W. H.
1800; 3 (1): 5-15

- Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis
  Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B., Khodadoust, M. S., Jin, M. C., Bru, A., Liu, C., Stehr, H., Vineis, P., Natkunam, et al
AMER SOC HEMATOLOGY. 2021

- Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
  Spasevska, I., Sharma, A., Steen, C. B., Josefsson, S., Blaker, Y., Rustad, E. H., Meyer, S., Chellappa, S., Kushekhar, K., Kolstad, A., Beiske, K., Holte, H., Ostenstad, et al
AMER SOC HEMATOLOGY. 2021

- Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib
  Roschewski, M., Phelan, J. D., Pittaluga, S., Melani, C., Lakhotia, R., Chabon, J. J., Muppidi, J. R., Lurain, K. A., Simard, J., Pradhan, A., Hillsman, A., Rilko, M., Steinberg, et al
AMER SOC HEMATOLOGY. 2021

- S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements
  Brem, E. A., Li, H., Beaven, A. W., Caimi, P. F., Cerchietti, L., Alizadeh, A. A., Olin, R. L., Henry, N., Dillon, H., Little, R. F., Laubach, C., Leblanc, M. L., Friedberg, et al
AMER SOC HEMATOLOGY. 2021

- Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing
  Esfahani, M., Alig, S., Mehrmohamadi, M., Hamilton, E. G., King, D. A., Schultz, A., Steen, C. B., Macaulay, C., Sworder, B., Kurtz, D. M., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY. 2021
• Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma
  Lynch, R. C., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Shustov, A. R., Till, B. G., Tseng, Y. D., Coye, H., Shelby, M., Ottemiller, S., Du, et al
  AMER SOC HEMATOLOGY.2021

• Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
  Shree, T., Shankar, V., Czerwinsk, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., Advani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Kurtz, D. M., Corbelli, K. S., Gabriel, et al
  AMER SOC HEMATOLOGY.2021

• SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. Journal of geriatric oncology
  Brem, E. A., Li, H., Beaver, A. W., Caimi, P. F., Cerchietti, L., Alizadeh, A. A., Olin, R., Henry, N. L., Dillon, H., Little, R. F., Laubach, C., LeBlanc, M., Friedberg, et al
  2021

• Circulating tumor DNA profiling for noninvasive detection, classification, and risk stratification of patients with CNS lymphomas
  Mutter, J. A., Alig, S., Lauer, E. M., Esfahani, M. S., Mitschke, J., Kurtz, D. M., Olsen, M., Liu, C. L., Jin, M. C., Bleul, S., Macaulay, C. W., Neidert, N. N., Heiland, et al
  KARGER.2021: 90

• A comprehensive circulating tumor DNA assay for detection of translocation and copy number changes in pediatric sarcomas. Molecular cancer therapeutics
  Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Strassler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H., Behroozfard, I. H., Wittmer, F. M., Hazard, et al
  2021

• Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.
  Kurtz, D., Chabon, J. J., Sworder, B., Keh, L., Soo, J., Alig, S., Schultz, A., Garofalo, A., Hamilton, E. G., Chen, B., Olsen, M., Moding, E., Liu, et al
  LIPPINCOTT WILLIAMS & WILKINS.2021

• Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.
  Moding, E., Hui, A. B., Murciano-Goroff, Y. R., Nabet, B., Schultz, A., Qiao, Y., Li, B. T., Lin, S. H., Alizadeh, A. A., Diehn, M.
  LIPPINCOTT WILLIAMS & WILKINS.2021

• Phased variants improve DLBCL minimal residual disease detection at the end of therapy.
  Kurtz, D., Chabon, J. J., Soo, J., Keh, L., Alig, S., Schultz, A., Jin, M. C., Scherer, F., Craig, A. M., Liu, C., Duehrsen, U., Huettmann, A., Casasnovas, et al
  LIPPINCOTT WILLIAMS & WILKINS.2021

• Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
  Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., Yoo, C., Kurtz, D. M., Owen, S., Backhus, L. M., Berry, M. F., Shragger, J. B., Ramchandran, et al
  AMER ASSOC CANCER RESEARCH.2021

• Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
  Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z., Das, M., Ramchandran, K. J., Padda, S. K., Neal, et al
  AMER ASSOC CANCER RESEARCH.2021

• Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer discovery
  Moding, E. J., Nabet, B. Y., Alizadeh, A. A., Diehn, M.
  2021

• A mathematical model of ctDNA shedding predicts tumor detection size. Science advances
  Avanzini, S., Kurtz, D. M., Chabon, J. J., Moding, E. J., Hori, S. S., Gambhir, S. S., Alizadeh, A. A., Diehn, M., Reiter, J. G.
  2020; 6 (50)

• Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
  Spasevskas, I.,Josefsson, S., Blaker, Y., Steen, C. B., Sharma, A., Kushekhar, K., Meyer, S., Kolstad, A., Beiske, K., Holte, H., Ostenstad, B., Kimby, E., Olweus, et al
  AMER SOC HEMATOLOGY.2020
• CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering
  Majzner, R. G., Frank, M. J., Mount, C., Tousley, A., Kurtz, D. M., Sworder, B., Murphy, K. A., Manousopoulou, A., Kohler, K., Rötiroti, M., Spiegel, J. Y., Natkunam, Y., Younes, et al
  AMER SOC HEMATOLOGY.2020

• Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)
  Shukla, N. D., Craig, A. M., Sworder, B., Kurtz, D. M., Macaulay, C., Garofalo, A., Frank, M. J., Alig, S., Duran, G., Kim, Y. H., Zehnder, J., Mackall, C. L., Miklos, et al
  AMER SOC HEMATOLOGY.2020

• Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma
  Greenwell, I., Switchenko, J. M., Maddocks, K. J., Kahl, B. S., Craig, A. M., Alizadeh, A. A., Allen, P. B., Marbury, A., Escobar, A., Valla, K., Williams, M., Parikh, P., Roberts, et al
  AMER SOC HEMATOLOGY.2020

• Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage
  Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B., Khodadoust, M. S., Jin, M. C., Bru, A., Liu, C., Stehr, H., Vineis, P., Natkunam, et al
  AMER SOC HEMATOLOGY.2020

• A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
  Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C., Hui, A. B., Stehr, H., Goljenola, L., Jin, et al
  AMER ASSOC CANCER RESEARCH.2020

• Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors
  Luca, B. A., Steen, C. B., Azizi, A., Matusiak, M., Przybyl, J., Neishaboori, N., Perez, A., Diehn, M., Alizadeh, A. A., van de Rijn, M., Gentles, A. J., Newman, A. M.
  AMER ASSOC CANCER RESEARCH.2020

• Chromatin accessibility patterns in cell-free DNA reveal tumor heterogeneity
  Esfahani, M., Mehrmohamadi, M., Steen, C. B., Hamilton, E. G., King, D. A., Soo, J., Macaulay, C., Jin, M., Kurtz, D. M., Nabet, B., Moding, E., Chabon, J., Newman, et al
  AMER ASSOC CANCER RESEARCH.2020

• ctDNA shedding dynamics dictate early lung cancer detection potential
  Avanzini, S., Kurtz, D. M., Chabon, J. J., Hori, S. S., Alizadeh, A. A., Diehn, M., Reiter, J. G.
  AMER ASSOC CANCER RESEARCH.2020: 25

• Analytical validation of iSort digital cytometry for leukocyte enumeration in clinical tumor specimens.
  Newman, A. M., Nakao, A., Li, K., Wilson, D., Liu, C., Diehn, M., Alizadeh, A. A.
  LIPPINCOTT WILLIAMS & WILKINS.2020

• Analytical validation of digital cytometry (iSort) for leukocyte enumeration using stored blood.
  Newman, A. M., Nakao, A., Li, K., Liu, C., Mathi, K., Sigal, N., Macecker, H., Diehn, M., Alizadeh, A. A.
  AMER SOC CLINICAL ONCOLOGY.2020

• A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
  Moding, E. J., Esfahani, M., Nabet, B., Liu, Y., Chabon, J. J., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z. X., Das, M., Ramchandran, et al
  AMER SOC CLINICAL ONCOLOGY.2020

• Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer.
  Murciano-Goroff, Y. R., Hui, A. B., Chabon, J. J., Moding, E. J., Lebow, E. S., Araujo-Filho, J. A., Isbell, J. M., Jones, D., Ginsberg, M. S., Myers, M. L., Offin, M., Drilon, A. E., Hellmann, et al
  AMER SOC CLINICAL ONCOLOGY.2020

• KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
  Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., Yoo, C., Kurtz, D., Owen, S., Backhus, L., Berry, M. F., Shrager, J. B., Ramchandran, et al
  AMER SOC CLINICAL ONCOLOGY.2020
• Next Generation Sequencing of Cerebrospinal Fluid to Improve Diagnostic Sensitivity, Detect Spatial Heterogeneity, and Predict Outcomes for Advanced Lung Cancer Patients with Leptomeningeal Carcinomatosis
  Azad, T., Nanjo, S., Chabon, J., Jin, M., Connolly, I., Ko, R., Yoo, C., Iv, M., Nagpal, S., Gephart, M., Alizadeh, A., Diehn, M. AMER ASSOC NEUROLOGICAL SURGEONS.2020: 110

• Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma
  Shyam, R., Kurtz, D., Alig, S., Jin, M., Link, M., Marks, L., Alizadeh, A. GEORG THIEME VERLAG KG.2020: 81

• Detection of circulating tumor DNA in pancreas cancer
  King, D., Alizadeh, A. A., Fisher, G. A. AMER SOC CLINICAL ONCOLOGY.2020

• Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature cancer, Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., Jones, C. D., He, J., Qiao, et al 2020; 1 (2): 176-183

• Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. Methods in molecular biology (Clifton, N.J.) Steen, C. B., Liu, C. L., Alizadeh, A. A., Newman, A. M. 2020; 2117: 135–57

• Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, Accomando, W. P., Rao, A. R., Hogan, D. J., Newman, A. M., Nakao, A. n., Alizadeh, A. A., Diehn, M. n., Diago, O. R., Gammon, D. K., Haghjighi, A. n., Gruber, H. E., Jolly, D. J., Ostertag, et al 2020

• Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research, Hellmann, M. D., Nabet, B. Y., Rizvi, H. n., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., Luo, J. n., Preeshagul, I. R., Moding, et al 2020

• Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nature communications, Wisdom, A. J., Mowery, Y. M., Hong, C. S., Himes, J. E., Nabet, B. Y., Qin, X. n., Zhang, D. n., Chen, L. n., Fradin, H. n., Patel, R. n., Bassil, A. M., Muise, E. S., King, et al 2020; 11 (1): 6410

• Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood advances, Ali, G. n., Jurinovic, V. n., Shahrokhi Esfahani, M. n., Haeb, S. n., Passerini, V. n., Hellmuth, J. C., Gaitzsch, E. n., Keay, W. n., Tahiri, N. n., Zoellner, A. n., Rosenwald, A. n., Klapper, W. n., Stein, et al 2020; 4 (18): 4451–62

• KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer discovery, Binkley, M. S., Jeon, Y. J., Nesselbush, M. n., Moding, E. J., Nabet, B. Y., Almanza, D. n., Kunder, C. n., Stehr, H. n., Yoo, C. H., Rhee, S. n., Xiang, M. n., Chabon, J. J., Hamilton, et al 2020

• Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer NATURE CANCER, Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Gojenola, L., Jones, C. D., He, J., Qiao, Y., Heymach, et al 2020; 1: 176–183

• Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase II/II trial. The Journal of experimental medicine, Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al 2020; 217 (9)

• Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA oncology
Phillips, R. n., Shi, W. Y., Deek, M. n., Radwan, N. n., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C. n., Greco, S. C., Wang, H. n., Denmeade, et al

2020

• An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
Steen, C. B., Luca, B. A., Esfahani, M., Nabet, B. Y., Sworder, B., Farshidfar, F., Shamardani, K., Kurtz, D. M., Liu, C., Advani, R. H., Natkunam, Y., Myklebust, J., Diehn, et al
AMER SOC HEMATOLOGY.2019

• Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment
Wagar, L. E., Sworder, B., Khodadoust, M. S., Davis, M. M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2019

• Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation
Kathuria, K. R., Chen, B., Khodadoust, M. S., Olsson, N., Davis, M. M., Elias, J. E., Levy, R., Altman, R. B., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2019

• Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies
Garofalo, A., Schroers-Martin, J. G., Soo, J., Kurtz, D. M., Sworder, B., Liu, C., Pinsky, B. A., Luikart, H., Advani, R. H., Natkunam, Y., Khush, K., Diehn, M., Alizadeh, et al
AMER SOC HEMATOLOGY.2019

• Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors
Luca, B., Alizadeh, A., Diehn, M., Newman, A., Gentles, A., Steen, C.
BMC.2019

• Broad Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer
Nair, V., Hui, A., Chabon, J., Esfahani, M., Stehr, H., Nabet, B., Benson, J., Chaudhuri, A., Zhou, L., Ayers, K., Bedi, H., Ramsey, M., Van Wert, et al
ELSEVIER SCIENCE INC.2019: S747–S748

• Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes
Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Binkley, M. S., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, et al
ELSEVIER SCIENCE INC.2019: S113

• Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Science translational medicine
Jain, N., Hartert, K., Tadros, S., Fiskus, W., Havranek, O., Ma, M. C., Bouska, A., Heavican, T., Kumar, D., Deng, Q., Moore, D., Pak, C., Liu, et al
2019; 11 (497)

• ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., He, J., Qiao, Y., Heymach, J., Tsao, A. S., Liao, Z. X., Gomez, D., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2019

• Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA
Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D., D'Emilio, N., Luikart, H., Alizadeh, A., Khush, K.
ELSEVIER SCIENCE INC.2019: S12–S13

• Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply JOURNAL OF CLINICAL ONCOLOGY
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; 37 (9): 755+4

• B-cell lymphomas present immunoglobulin neoantigens BLOOD
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C., Zhang, L., Czerwinski, D. K., Davis, M. M., Levy, R., Elias, J. E., Alizadeh, A. A.
2019; 133 (8): 878–81

• Reply to J. Wang et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019: JCO1801907

• Spatial mapping of the immune microenvironment in primary triple-negative breast cancer (TNBC) and association with neoadjuvant therapy response
Telli, M. L., Vinayak, S., Khododoust, M. S., Gruber, J. J., Ford, J. M., Sanchez, P., Banayan, N., Azimi, S., Tumeh, P. C., Newman, A. M., Alizadeh, A. A.
AMER ASSOC CANCER RESEARCH.2019

- Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy American Society of Hematology
  Sworder, B., Kurtz, D. M., Macaulay, C., Frank, M. J., Alig, S., Garofalo, A., Sahaf, B., Esfahani, M. S., Spiegel, J. Y., Oak, J., Beygi, S., Jin, M. C., Chabon, et al 2019

- Functional significance of U2AF1 S34F mutations in lung adenocarcinomas Nature Communications
  Shahrokh Esfahani, M.
  2019; 10

- Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nature communications
  Esfahani, M. S., Lee, L. J., Jeon, Y. J., Flynn, R. A., Stehr, H. n., Hui, A. B., Ishisoko, N. n., Kildebeck, E. n., Newman, A. M., Bratman, S. V., Porteus, M. H., Chang, H. Y., Alizadeh, et al
  2019; 10 (1): 5712

- Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology
  Azad, T. D., Chaudhuri, A. A., Fang, P. n., Qiao, Y. n., Esfahani, M. S., Chabon, J. J., Hamilton, E. G., Yang, Y. D., Lovejoy, A. n., Newman, A. M., Kurtz, D. M., Jin, M. n., Schroers-Martin, et al
  2019

- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL American Society of Hematology
  Macaulay, C., Alig, S., Kurtz, D. M., Jin, M. C., Opat, S., Soo, J., Sworder, B., Hertzberg, M. S., Gandhi, M. K., Diehn, M., Alizadeh, A. A.
  2019

- Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma American Society of Hematology
  Alig, S., Macaulay, C., Kurtz, D. M., Ulrich, D., Andreas, H., Jin, M. C., Sworder, B., Garofalo, A., Esfahani, M. S., Soo, J., Scherer, F., Craig, A., Casasnovas, et al
  2019

- Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA American Society of Hematology
  Kurtz, D. M., Soo, J., Alig, S., Keh, L. C., Macaulay, C., Jin, M. C., Scherer, F., Hamilton, E. G., Liu, C., Chen, B., Craig, A., Diehn, M., Alizadeh, et al
  2019

- Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling American Society of Hematology
  Esfahani, M. S., Alig, S., Kurtz, D. M., Soo, J., Jin, M. C., Macaulay, C., Craig, A., Garofalo, A., Steen, C. B., Scherer, F., Sworder, B., Diehn, M., Alizadeh, et al
  2019

- Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing
  Schroers-Martin, J. G., Garofalo, A., Soo, J., Jin, M. C., Kurtz, D. M., Buedts, L., Dehursen, U., Huetttmann, A., Cottereau, A., Meignan, M., Casasnovas, O., Westin, J. R., Gaidano, et al
  AMER SOC HEMATOLOGY.2018

- Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling
  Mehrmohamadi, M., Esfahani, M. S., Soo, J., Scherer, F., Schroers-Martin, J. G., Chen, B., Kurtz, D. M., Hamilton, E., Liu, C., Diehn, M., Alizadeh, A. A.
  AMER SOC HEMATOLOGY.2018

- Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
  Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., Sworder, B., Soo, J., Glover, C., Roscchewski, M., Wilson, W. H., Dehursen, U., Huetttmann, et al
  AMER SOC HEMATOLOGY.2018

- Analysis of Circulating Tumor DNA Kinetics during Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer
  Chen, E. L., Chaudhuri, A. A., Nabet, B. Y., Chabon, J. J., Merriott, D. J., Loo, B. W., Alizadeh, A. A., Diehn, M.
  ELSEVIER SCIENCE INC.2018: E676

- Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst COLD SPRING HARBOR MOLECULAR CASE STUDIES
Erdrich, J., Schaberg, K. B., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., Beausang, J. F. 2018; 4 (5)

- Quantitating circulating tumor DNA in translocation-positive sarcoma patients using CAPP-Seq
  Shah, A., Azad, T. D., Chabon, J. J., Breese, M., Tanasa, B., Spillinger, A., Leung, S. G., Diehn, M., Alizadeh, A. A., Sweet-Cordero, E. AMER ASSOC CANCER RESEARCH.2018

- Circulating tumor DNA (ctDNA) in B-cell lymphoma
  Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al WILEY.2018: 16–17

- Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor molecular case studies
  Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., Beausang, J. F. 2018

- Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
  Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., Newman, A. M., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H., Das, et al ELSEVIER SCIENCE INC.2018: E1–E2

- Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma CLINICAL CANCER RESEARCH
  Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K. N., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A. A., Diehn, M., van de Rijn, et al 2018; 24 (11): 2688–99

- Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA.
  Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D., D'Emilio, N., Grimm, D. AMER SOC CLINICAL ONCOLOGY.2018

- Post-transplant head and neck cancers: A prospective analysis of clinical factors for risk stratification.
  Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D., D'Emilio, N., Grimm, D. AMER SOC CLINICAL ONCOLOGY.2018

- Genomic Feature Selection by Coverage Design Optimization. Journal of applied statistics
  Reid, S., Newman, A. M., Diehn, M., Alizadeh, A. A., Tibshirani, R. 2018; 45 (14): 2658-2676

- Circulating tumor DNA levels correlate with response to treatment in LMS patients
  Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A., Diehn, M., van de Rijn, et al AMER ASSOC CANCER RESEARCH.2018: 38–39

- Detection and surveillance of bladder cancer using urine tumor DNA. Cancer discovery
  Dudley, J. C., Schroers-Martin, J. n., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., Trivedi, D. n., Chabon, J. J., Chaudhuri, A. A., Stehr, H. n., Liu, C. L., Lim, H. n., Costa, et al 2018

- Genomic Profiling of Bronchoalveolar Lavage Fluid in Patients with Non-Small Cell Lung Cancer
  Nair, V. S., Li, A., Stehr, H., Chabon, J., Chaudhuri, A., Zhou, L., Naemi, H., Ayers, K., Ramsey, M., Bedi, H. S., Van Wert, R., Sung, A. W., Lui, et al AMER THORACIC SOC.2018

- Genomic feature selection by coverage design optimization Journal of Applied Statistics
  Reid, S., Newman, A. M., Diehn, M., Alizadeh, A. A., Tibshirani, R. 2018

- Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research
  Przybyl, J. n., Chabon, J. J., Spans, L. n., Ganjoo, K. n., Vennam, S. n., Newman, A. M., Forgó, E. n., Varma, S. n., Zhu, S. n., Debiec-Rychter, M. n., Alizadeh, A. A., Diehn, M. n., van de Rijn, et al
• Profiling Tumor Infiltrating Immune Cells with CIBERSORT. *Methods in molecular biology (Clifton, N.J.)*

Chen, B. n., Khodadoust, M. S., Liu, C. L., Newman, A. M., Alizadeh, A. A.
2018; 1711: 243–59

• Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma

Kurtz, D. M., Scherer, F., Jin, M., Soo, J., Craig, A., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
AMER SOC HEMATOLOGY.2017

• Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome

Chen, B., Khodadoust, M., Olsson, N., Fast, E., Waglar, L. E., Liu, C., Davis, M., Levy, R., Elias, J. E., Altman, R. B., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2017

• Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis

Schroers-Martin, J. G., Scherer, F., Soo, J., Kurtz, D. M., Liu, C., Stehr, H., Bru, A., Natkunam, Y., Diehn, M., Nadel, B., Roulland, S., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2017

• Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes

Jin, M., Kurtz, D. M., Esfahani, M. S., Soo, J., Craig, A., Scherer, F., Stehr, H., Schroers-Martin, J. G., Bangs, C., Cherry, A., Natkunam, Y., Roschewski, M., Wilson, et al
AMER SOC HEMATOLOGY.2017

• Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens

Soo, J., Scherer, F., Kurtz, D. M., Schroers-Martin, J. G., Jin, M., Craig, A., Stehr, H., Liu, C., Green, M. R., Weigert, O., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2017

• Comparison of Circulating Tumor DNA Recovery from Plasma and Serum

Soo, J., Kurtz, D. M., Jin, M., Scherer, F., Schroers-Martin, J. G., Esfahani, M. S., Craig, A., Stehr, H., Neelapu, S. S., Nastoupil, L., Roschewski, M., Wilson, W. H., Diehn, et al
AMER SOC HEMATOLOGY.2017

• Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes

Schroers-Martin, J. G., Kurtz, D. M., Soo, J., Jin, M., Scherer, F., Craig, A., Chabon, J. J., Liu, C., Stehr, H., Duehrsen, U., Huttmann, A., Cottereau, A., Meignan, et al
AMER SOC HEMATOLOGY.2017

• Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study

Kurtz, D. M., Jin, M., Soo, J., Scherer, F., Craig, A., Chabon, J. J., Schroers-Martin, J. G., Liu, C., Stehr, H., Schmitz, C., Duehrsen, U., Huttmann, A., Cottereau, et al
AMER SOC HEMATOLOGY.2017

• KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*

Kunder, C. A., Roncador, G., Advani, R. H., Gualco, G., Bacchi, C. E., Sabile, J. M., Lososso, I. S., Nie, K., Tibshirani, R., Green, M. R., Alizadeh, A. A., Natkunam, Y.
2017; 148 (6): 465–76

• Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA

Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., Martin, J., Merriott, D., Carter, J., Ayers, K., Mansfield, A., Jen, J., Ren, et al
ELSEVIER SCIENCE INC.2017: S1851

• Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer

Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C. L., Kurtz, D. M., Gensheimer, M. F., Shrager, J. B., Wakelee, et al
ELSEVIER SCIENCE INC.2017: S114

• Pretreatment Circulating Tumor DNA for Risk Stratification of Locally Advanced Esophageal Cancer Treated With Chemoradiation and Surgery

Azad, T. D., Chaudhuri, A. A., Newman, A., Stehr, H., Schroers-Martin, J., Chabon, J. J., Fang, P., Qiao, Y., Liao, Z., Komaki, R. U., Alizadeh, A. A., Lin, S. H., Diehn, et al
ELSEVIER SCIENCE INC.2017: S90–S91
• Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H. R., Das, M., Padda, S., Loo, et al
ELSEVIER SCIENCE INC.2017: S20–S21

• Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., Carter, J. N., Azad, T. D., Padda, S., Gensheimer, M. F., Wakelee, H. A., Neal, J. W., Loo, et al
ELSEVIER SCIENCE INC.2017: S1–S2

• On the hunt for cancer neoantigens: is mass spectrometry the solution?
Elias, J., Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Green, M. R., Davis, M. M., Levy, R., Alizadeh, A. A.
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC.2017: S65

• Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance
Jeong, Y., Ngoc Hoang, Stehr, H., Lovejoy, A., Gentles, A., Chaudhuri, A., Loo, B., Alizadeh, A., Diehn, M.
AMER ASSOC CANCER RESEARCH.2017

• Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Zhou, L., Liu, C., Scherer, F., Kurtz, D. M., Esfahani, M. S., Say, C., Carter, et al
ELSEVIER SCIENCE INC.2017: E4

• Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer.
Azad, T. D., Chaudhuri, A., Newman, A. M., Stehr, H., Schroers-Martin, J., Chabon, J. J., Fang, P., Qiao, Y., Liao, Z. X., Komaki, R., Alizadeh, A. A., Lin, S. H., Diehn, et al
AMER SOC CLINICAL ONCOLOGY.2017

• Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).
Diehn, M., Alizadeh, A. A., Adams, H., Lee, J. J., Klassen, S., Palma, J. F., Hinzman, B., Lovejoy, A. F., Newman, A. M., Yao, L., Yaung, S., Balasubramanyam, A., Rohr, et al
AMER SOC CLINICAL ONCOLOGY.2017

• Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.
Chaudhuri, A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C., Kurtz, D., Dudley, J. C., Padda, S., Shrager, et al
AMER SOC CLINICAL ONCOLOGY.2017

• Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.
Soo, J., Kurtz, D., Scherer, F., Craig, A. M., Jin, M. C., Westin, J. R., Rossi, D., Gaidano, G., Advani, R. H., Diehn, M., Alizadeh, A. A.
AMER SOC CLINICAL ONCOLOGY.2017

• Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.
Jin, M. C., Kurtz, D., Esfahani, M., Scherer, F., Craig, A. M., Soo, J., Khodadoust, M., Saganty, R., Chabon, J. J., Schroers-Martin, I., Stehr, H., Advani, R. H., Rossi, et al
AMER SOC CLINICAL ONCOLOGY.2017

• overexpression to promote lymphoma in mice. Blood
García-Ramírez, I., Tadros, S., González-Herrero, I., Martín-Lorenzo, A., Rodríguez-Hernández, G., Moore, D., Ruiz-Roca, L., Blanco, O., Alonso-López, D., Rivas, J. D., Hartert, K., Duval, R., Klinkebiel, et al
2017; 129 (19): 2645-2656

• Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice BLOOD
García-Ramírez, I., Tadros, S., Gonzalez-Herrero, I., Martin-Lorenzo, A., Rodriguez-Hernandez, G., Moore, D., Ruiz-Roca, L., Blanco, O., Alonso-Lopez, D., De Las Rivas, J., Hartert, K., Duval, R., Klinkebiel, et al
2017; 129 (19): 2645-2656

• Antigen presentation profiling reveals T-cell recognition of lymphoma immunoglobulin neoantigens
Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Haabeth, O., Chen, B., Rawson, K., Liu, C., Steiner, D., Lund, P. J., Rao, S., Zhang, L., Marceau, et al
AMER ASSOC IMMUNOLOGISTS.2017

• Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens NATURE
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A., Chen, B., Swaminathan, K., Rawson, K., Liu, C. L., Steiner, D., Lund, P., Rao, S., Zhang, L., Marceau, et al
2017; 543 (7647): 723-?

- Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. *Blood*
  Myklebust, J. H., Brody, J., Kohrt, H. E., Kolstad, A., Czerwinski, D. K., Wålchli, S., Green, M. R., Trøen, G., Liestøl, K., Beiske, K., Houot, R., Delabie, J., Alizadeh, et al
  2017; 129 (6): 759-770

- Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance *CANCER DISCOVERY*
  Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Diana Truong, D., Martin, S., Chaudhuri, A., Heiser, D., Zhou, L., Say, et al
  2017; 7 (1): 86-101

- Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
  Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., Carter, J., Zhou, L., West, R., Shrager, J., Neal, J., Wakelee, H., Loo, et al
  ELSEVIER SCIENCE INC.2017: S445

- Data normalization considerations for digital tumor dissection. *Genome biology*
  Newman, A. M., Gentles, A. J., Liu, C. L., Diehn, M. n., Alizadeh, A. A.
  2017; 18 (1): 128

- High-throughput sequencing for noninvasive disease detection in hematologic malignancies. *Blood*
  Scherer, F. n., Kurtz, D. M., Diehn, M. n., Alizadeh, A. A.
  2017; 130 (4): 440-52

- Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. *Cancer discovery*
  Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H. n., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L. n., Scherer, F. n., Kurtz, D. M., Say, et al
  2017

- Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA
  Scherer, F., Kurtz, D. M., Newman, A. M., Craig, A., Stehr, H., Zhou, L., Glover, C., Kohrt, H., Levy, R., Diehn, M., Alizadeh, A. A.
  AMER SOC HEMATOLOGY.2016

- Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
  Khodadoust, M., Rook, A. H., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., Shanbhag, S., Sokol, L., Shine, R., Fligl, S. P., Li, S., Rabhar, Z., Kim, et al
  AMER SOC HEMATOLOGY.2016

- Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma
  Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., Chabon, J. J., Esfahani, M., Liu, C., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
  AMER SOC HEMATOLOGY.2016

- Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations
  Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Glover, C., Levy, R., Kunder, et al
  AMER SOC HEMATOLOGY.2016

- Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma *58th Annual Meeting and Exposition of the American-Society-of-Hematology*
  Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., Lovejoy, A. F., Chabon, J. J., Liu, C. L., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
  AMER SOC HEMATOLOGY.2016

- DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma
  Hartert, K., Tadros, S., Bouska, A., Moore, D., Pak, C., Heavican, T., Liu, C., Gentles, A. J., Hartmann, E. M., Kriedel, R., Smedby, K., Julliusson, G., Rosenquist, et al
  AMER SOC HEMATOLOGY.2016

- Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens
  Khodadoust, M., Olsson, N., Wagar, L., Chen, B., Rawson, K., Liu, C., Steiner, D., Rao, S., Zhang, L., Stehr, H., Newman, A. M., Czerwinski, D. K., Carlton, et al
  AMER SOC HEMATOLOGY.2016
• CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., Aggarwal, S., Carter, J. N., West, R. B., Neal, J. W., Wakelee, H. A., Loo, B. W., Alizadeh, et al
ELSEVIER SCIENCE INC. 2016: S41–S42

• A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
Ott, P. A., Pavlick, A. C., Johnson, D. B., Hart, L. L., Infante, J. R., Luke, J. J., Lutzky, J., Rothschild, N., Spitler, L., Cowey, C. L., Alizadeh, A., Salama, A., He, et al
OXFORD UNIV PRESS. 2016

• Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer discovery
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., Heiser, D., Zhou, L., Say, et al 2016

• High-throughput genomic profiling of tumor-infiltrating leukocytes. Current opinion in immunology
Newman, A. M., Alizadeh, A. A.
2016; 41: 77-84

• Noninvasive molecular subtyping and risk stratification of DLBCL.
Scherer, F., Kurtz, D., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C., Zhou, L., Glover, C., Advani, et al
AMER SOC CLINICAL ONCOLOGY. 2016

• Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.
Kurtz, D., Scherer, F., Newman, A. M., Craig, A. M., Khodadoust, M., Lovejoy, A. F., Klass, D. M., Chabon, J. J., Glover, C., Zhou, L., Liu, C., Gupta, N. K., Maeda, et al
AMER SOC CLINICAL ONCOLOGY. 2016

• Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D., Chabon, J. J., Scherer, F., Stehr, H., Liu, C., Bratman, S., Say, C., Zhou, L., Carter, J. N., West, et al
AMER SOC CLINICAL ONCOLOGY. 2016

• Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
Chabon, J., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., Kurtz, D., Stehr, H., Scherer, F., Durkin, K. A., Otterson, G., Purcell, W. T., Camidge, et al
AMER SOC CLINICAL ONCOLOGY. 2016

• Tumor Lesion Glycolysis as an Indicator of Prognosis in the pre-treatment Phase of Patients with DLBCL
Flynt, L., Quon, A., Alizadeh, A., Kurtz, D.
SOC NUCLEAR MEDICINE INC. 2016

• Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA
Esfahani, M., Newman, A. M., Scherer, F., Tibshirani, R., Diehn, M., Alizadeh, A. A., ACM ASSOC COMPUTING MACHINERY. 2016: 516

• Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Craig, A. M., Chabon, J. J., Lovejoy, A. F., Klass, D. M., Glover, C., Ohgami, R. S., Kunder, et al
AMER SOC HEMATOLOGY. 2015

• Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Newman, A. M., Lovejoy, A. F., Klass, D. M., Chabon, J. J., Gambhir, S., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY. 2015

• Organocatalytic removal of formaldehyde adducts from RNA and DNA bases (vol 7, pg 752, 2015) NATURE CHEMISTRY
Karmakar, S., Harcourt, E. M., Hewings, D. S., Scherer, F., Lovejoy, A. F., Kurtz, D. M., Ehrenschwender, T., Barandun, L. J., Roost, C., Alizadeh, A. A., Kool, E. T.
2015; 7 (12): 1033

• The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Yue, X., Khuong, A., Hoang, C. D., Diehn, M., West, R. B., Plevritis, et al
The VarScan2's SNVs-Near-Indel Filter: Is It Necessary?
Suarez, C. J., Stehr, H., Fung, E., Kunder, C. A., Ewalt, M. D., Lal, A., Alizadeh, A., Diehn, M., Schrijver, I., Zehnder, J.
ELSEVIER SCIENCE INC. 2015: 801

Analysis of Circulating Tumor DNA in Esophageal Carcinoma Patients Treated With Chemoradiation Therapy
Klass, D., Newman, A., Lovejoy, A. F., Zhou, L., Stehr, H., Xu, T., He, J., Komaki, R. U., Liao, Z., Maru, D., Alizadeh, A., Lin, S. H., Diehn, et al
ELSEVIER SCIENCE INC. 2015: S104–S105

Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Seminars in radiation oncology
Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A., Diehn, M.
2015; 25 (4): 305-312

Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. Journal of the National Cancer Institute
Gentles, A. J., Bratman, S. V., Lee, L. J., Harris, J. P., Feng, W., Nair, R. V., Shultz, D. B., Nair, V. S., Hoang, C. D., West, R. B., Plevritis, S. K., Alizadeh, A. A., Diehn, et al
2015; 107 (10)

Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. NATURE CHEMISTRY
Karmakar, S., Harcourt, E. M., Hewings, D. S., Lovejoy, A. F., Kurtz, D. M., Ehrenschwender, T., Barandun, L. J., Roost, C., Alizadeh, A. A., Kool, E. T.
2015; 7 (9): 752-758

Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PLOS ONE
Whiting, C. C., Siebert, J., Newman, A. M., Du, H., Alizadeh, A. A., Goronzy, J., Weyand, C. M., Krishnan, E., Fathman, C. G., Maecker, H. T.
2015; 10 (7)

Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.
Kurtz, D., Scherer, F., Green, M., Khodadoust, M., Klass, D. M., Zhou, L., Krishnan, R., Glover, C., Liu, C., Kong, K. A., Faham, M., Levy, R., Diehn, et al
AMER SOC CLINICAL ONCOLOGY. 2015

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)
Scherer, F., Kurtz, D., Green, M., Newman, A. M., Klass, D. M., Zhou, L., Krishnan, R., Liu, C., Glover, C., Ohgami, R. S., Hicks, R. J., Keane, C., Kong, et al
AMER SOC CLINICAL ONCOLOGY. 2015

Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC
Vinayak, S., Newman, A., Adams, S., Afghahi, A., Jensen, K. C., Badve, S. S., Ford, J. M., Alizadeh, A. A., Telli, M. L.
AMER ASSOC CANCER RESEARCH. 2015

Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert review of molecular diagnostics
Bratman, S. V., Newman, A. M., Alizadeh, A. A., Diehn, M. n.
2015: 1–5

Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PLoS one
Whiting, C. C., Siebert, J., Newman, A. M., Du, H., Alizadeh, A. A., Goronzy, J., Weyand, C. M., Krishnan, E., Fathman, C. G., Maecker, H. T.
2015; 10 (7)

A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
• Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria. *American Journal of Clinical Pathology*
  Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., Arber, D. A.  
  2014; 142 (6): 803-808

• Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing  
  Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, A.  
  Elsevier Science Inc. 2014: S75

• A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates. *Journal of the American Statistical Association*  
  Tian, L., Alizadeh, A. A., Gentles, A. J., Tibshirani, R.  
  2014; 109 (508): 1517-1532

• Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC  
  Modiin, L. A., Bratman, S. V., Newman, A. M., Ecolov, N. W., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Alizadeh, A. A., Diehn, M.  
  Elsevier Science Inc. 2014: S812

• Circulating Tumor DNA as a Biomarker for Pancreatic Adenocarcinoma  
  Osmundson, E., Newman, A. M., Bratman, S. V., Klass, D. M., Zhou, L., Pai, J., Longacre, T. A., Alizadeh, A. A., Koong, A. C., Diehn, M.  
  Elsevier Science Inc. 2014: S816-S817

• Common progenitor cells in mature B-cell malignancies: implications for therapy. *Current opinion in hematology*  
  Green, M. R., Alizadeh, A. A.  
  2014; 21 (4): 333-340

• Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. *Journal of clinical oncology*  
  Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al  
  2014; 32 (17): 1797-1803

• Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.  
  Kurtz, D., Green, M. R., Bratman, S., Liu, C., Glover, C., Keane, C., Kong, K., Faham, M., Miklos, D., Advani, R. H., Levy, R., Hertzberg, M. S., Gandhi, et al  
  Amer Soc Clinical Oncology. 2014

• Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.  
  Bratman, S., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Diehn, M., Alizadeh, A. A.  
  Amer Soc Clinical Oncology. 2014

• Tumor antigen discovery through translation of the cancer genome. *Immunologic research*  
  Khodadoust, M. S., Alizadeh, A. A.  
  2014; 58 (2-3): 292-299

• Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. *Nature communications*  
  Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., García-Ramírez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., Campos-Sánchez, E., Orfao, A., Pintado, et al  
  2014; 5: 3904-?

• Hit-and-run lymphomagenesis by the Bcl6 oncogene. *Cell cycle*  
  Green, M. R., Vicente-Dueñas, C., Alizadeh, A. A., Sánchez-García, I.  
  2014; 13 (12): 1831-1832

• Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM  
  Myklebust, J., Brody, J., Alizadeh, A. A., Czerwinski, D. K., Kolstad, A., Green, M. R., Houot, R., Delabie, J., Kohrt, H. E., Irish, J. M., Levy, R.  
  Amer Soc Hematology. 2013
• Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing
  Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., Shrager, J., Loo, B. W., Alizadeh, A. A., Diehn, M.
  ELSEVIER SCIENCE INC.2013: S92

• Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy  SURGICAL ONCOLOGY- OXFORD
  Yang, J., Du, X.
  2013; 22 (3): E53-E57

• Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. Clinical immunology
  Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Tibshirani, R. J., Strober, S., Sarwal, M., Lowsky, R.
  2013; 148 (1): 124-135

• Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma. Blood
  Gentles, A. J., Alizadeh, A. A.
  2013; 121 (15): 3052-3054

• Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study. Leukemia & lymphoma
  Keegan, T. H., Moy, L. M., Foran, J. M., Alizadeh, A. A., Chang, E. T., Shema, S. J., Schupp, C. W., Clarke, C. A., Glaser, S. L.
  2013; 54 (4): 743-751

• Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study LEUKEMIA & LYMPHOMA
  Keegan, T. H., Moy, L. M., Foran, J. M., Alizadeh, A. A., Chang, E. T., Shema, S. J., Schupp, C. W., Clarke, C. A., Glaser, S. L.
  2013; 54 (4): 743-751

• High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood
  Myklebust, J. H., Irish, J. M., Brody, J., Czerwinski, D. K., Houot, R., Kohrt, H. E., Timmerman, J., Said, J., Green, M. R., Delabie, J., Kolstad, A., Alizadeh, A. A., Levy, et al
  2013; 121 (8): 1367-1376

• Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas
  Kunder, C. A., Zhao, S., Martinez, E. G., Roncador, G., Alizadeh, A. A., Lossos, I. S., Natkunam, Y.
  NATURE PUBLISHING GROUP.2013: 338A–339A

• Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas
  Kunder, C. A., Zhao, S., Martinez, E. G., Roncador, G., Alizadeh, A. A., Lossos, I. S., Natkunam, Y.
  NATURE PUBLISHING GROUP.2013: 338A–339A

• Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nature communications
  Romero-Camarro, I., Jiang, X., Natkunam, Y., Lu, X., Vicente-Dueñas, C., Gonzalez-Herrero, I., Flores, T., Garcia, J. L., McNamara, G., Kunder, C., Zhao, S., Segura, V., Fontan, et al
  2013; 4: 1338-?

• The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses.
  Pachynski, R., Zabel, B., Monnier, J., Gentles, A., Swanson, C., Kohrt, H., Hadeiba, H., Alizadeh, A., Butcher, E.
  AMER ASSOC CANCER RESEARCH.2013

• Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation NATURE COMMUNICATIONS
  Romero-Camarro, I., Jiang, X., Natkunam, Y., Lu, X., Vicente-Duenas, C., Gonzalez-Herrero, I., Flores, T., Luis Garcia, J., McNamara, G., Kunder, C., Zhao, S., Segura, V., Fontan, et al
  2013; 4

• Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)
  Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Levy, R., Alizadeh, A. A.
  AMER SOC HEMATOLOGY.2012

• Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
  Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., Sarwal, M., Lowsky, R.
The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)
Coutinho, R., Newman, A. M., Rossignoli, G., Day, W., Miraki-Moud, F., Chaplin, T., Marzec, J., Petty, R. D., Iqbal, S., Matthews, J., Alizadeh, A. A., Gribben, J. G.
AMER SOC HEMATOLOGY.2012

Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)
Newman, A. M., Gentles, A. J., Plevritis, S. K., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2012

Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression Profiling of Single Cells: A Pilot Study 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)
Liu, C. L., Dai, B., Newman, A. M., Majeti, R., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2012

Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., Sarwal, M., Lowsky, R.
AMER SOC HEMATOLOGY.2012

Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)
Torchia, J. A., Ng, P. P., Chen, H., Kohrt, H. E., Marabelle, A., Alizadeh, A. A., Levy, R.
AMER SOC HEMATOLOGY.2012

Self-antigen recognition by follicular lymphoma B-cell receptors BLOOD
Sachen, K. L., Strohman, M. J., Singletary, J., Alizadeh, A. A., Kattah, N. H., Lossos, C., Mellins, E. D., Levy, S., Levy, R.
2012; 120 (20): 4182-4190

Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer 54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)
Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., Richardson, K., Newman, A. M., Alizadeh, A., Diehn, M.
ELSEVIER SCIENCE INC.2012: S713–S713

Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma PLOS ONE
Huse, K., Bakkebo, M., Walchli, S., Oksvold, M. P., Hilden, V. I., Forfang, L., Bredahl, M. L., Liestol, K., Alizadeh, A. A., Smeland, E. B., Myklebust, J. H.
2012; 7 (10)

Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia AMERICAN JOURNAL OF HEMATOLOGY
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., Bates, J., Sekeres, M. A., Coutre, S., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al
2012; 87 (10): 957-960

CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas Diagnostic and Therapeutic Implications AMERICAN JOURNAL OF PATHOLOGY
Anderson, M. W., Zhao, S., Freud, A. G., Czerwinski, D. K., Kohrt, H., Alizadeh, A. A., Houot, R., Azambuja, D., Biasoli, I., Morais, J. C., Spector, N., Molina-Kirsch, H. F., Warnke, et al
2012; 181 (3): 795-803

The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses JOURNAL OF EXPERIMENTAL MEDICINE
Pachynski, R. K., Zabel, B. A., Kohrt, H. E., Tejeda, N. M., Monnier, J., Swanson, C. D., Holzer, A. K., Gentles, A. J., Sperinde, G. V., Edalati, A., Hadeiba, H. A., Alizadeh, A. A., Butcher, et al
2012; 209 (8): 1427-1435

HIGH PD-1 EXPRESSION AND SUPPRESSED EFFECUTOR CYTOKINE SIGNALING DISTINGUISH T CELLS INFILTRATING FOLLICULAR LYMPHOMA TUMORS FROM PERIPHERAL T CELLS
Myklebust, J. H., Irish, J., Brody, J., Czerwinski, D., Houot, R., Kohrt, H., Timmerman, J., Green, M., Delabie, J., Kolstad, A., Alizadeh, A., Levy, R.
FERRATA STORTI FOUNDATION.2012: 121
• A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. *Leukemia & Lymphoma* Warsch, S., Hosein, P. J., Maeda, L. S., Alizadeh, A. A., Lossos, I. S. 2012; 53 (7): 1299-1305

• The chemoattractant chemerin as a natural tumor suppressive cytokine. *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)* Pachynski, R. K., Zabel, B., Tejeda, N., Monnier, J., Holzer, A. K., Gentles, A., Kohrt, H. E., Hadeiba, H., Alizadeh, A. A., Butcher, E. *American Society of Clinical Oncology*. 2012

• The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Proceedings of the National Academy of Sciences of the United States of America* Willingham, S. B., Volkmer, J., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., Lovelace, P., Scheeren, F. A., Chao, et al. 2012; 109 (17): 6662-6667

• First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma. *Journal of Clinical Microbiology* Powel, M. S., Alizadeh, A. A., Budvytiene, I., Schaeenman, J. M., Banaei, N. 2012; 50 (3): 1125-1127

• Three differentiation states risk-stratify bladder cancer into distinct subtypes (vol 109, pg 2078, 2012). *Proceedings of the National Academy of Sciences of the United States of America* Volkmer, J., Sahoo, D., Chin, R. K., Ho, P. L., Tang, C., Kurtova, A. V., Willingham, S. B., Pazhanisamy, S. K., Contreras-Trujillo, H., Storm, T. A., Lotan, Y., Beck, A. H., Chung, et al. 2012; 109 (9): 3600-3600

• Treatment advances have not improved the early death rate in acute promyelocytic leukemia. *Haematologica-The Hematology Journal* McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., Medeiros, B. C. 2012; 97 (1): 133-136

• Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies (vol 14, R25, 2012). *Arthritis Research & Therapy* Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J. 2012; 14 (4)

• Correction: Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. *Arthritis Research & Therapy* Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J. 2012; 14 (4): 403-?

• Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. *Arthritis Research & Therapy* Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J. 2012; 14 (1)

• Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)* Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., Faham, M., Advani, R., Kohrt, H. E., Alizadeh, A. A., Negrin, R. S., Weng, W., Sheehan, et al. *American Society of Hematology*. 2011: 1323–23

• Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia. *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)* Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A. A., Bates, J., Sekeres, M. A., Coutre, S. E., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al. *American Society of Hematology*. 2011: 1095
• HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation
  Jiang, X., Romero-Camarero, I., Lu, X., Vicente-Duenas, C., Gonzalez-Herrero, I., Flores, T., Luis Garcia, J., McNamara, G., Kunder, C., Natkunam, Y., Segura, V., Fontan-Gabas, L., Martinez-Climent, et al
  AMER SOC HEMATOLOGY. 2011: 269

• A few good genes Simple, biologically motivated signatures for cancer prognosis  CELL CYCLE
  Gentles, A. J., Alizadeh, A. A.
  2011; 10 (21): 3615-3616

• A proteomic approach for the identification of novel lysine methyltransferase substrates  EPigenetics & CHROMatin
  Levy, D., Liu, C. L., Yang, Z., Newman, A. M., Alizadeh, A. A., Utz, P. J., Gozani, O.
  2011; 4

• Utility of positron emission tomography scans in mantle cell lymphoma  AMERICAN JOURNAL OF HEMATOLOGY
  Hosein, P. J., Pastorini, V. H., Paes, F. M., Eber, D., Chapman, J. R., Serafini, A. N., Alizadeh, A. A., Lossos, I. S.
  2011; 86 (10): 841-845

• Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors  HEMATOLOGICAL ONCOLOGY
  Pollyea, D. A., Raval, A., Kuster, B., Gotlob, J. R., Alizadeh, A. A., Mitchell, B. S.
  2011; 29 (3): 157-160

• Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia  CANCER CELL
  Alizadeh, A. A., Majeti, R.
  2011; 20 (2): 135-136

• Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment  BLOOD
  Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R. H., Gascoyne, R. D., Briones, J., Tibshirani, et al
  2011; 118 (5): 1350-1358

• Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results.
  Brody, J., Advani, R., Weng, W., Czerwinski, D., Alizadeh, A. A., Kohrt, H. E., Negrin, R., Levy, R.
  AMER SOC CLINICAL ONCOLOGY. 2011

• Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
  Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., Majeti, R.
  2011; 108 (12): 5009-5014

• Leukemic Stem Cell Gene Expression Signature and Clinical Outcomes in Acute Myeloid Leukemia Reply  JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
  Gentles, A. J., Majeti, R., Alizadeh, A. A.
  2011; 305 (11): 1094

• CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies  BLOOD
  Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Mueller, A., Pachynski, R., Czerwinski, D., Coutre, S., Chao, M. P., Chen, L., Tedder, et al
  2011; 117 (8): 2423-2432

• Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia  CANCER RESEARCH
  Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., Majeti, R.
  2011; 71 (4): 1374-1384

• NONINVASIVE PREDICTION OF GRAFT-VERUS-HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BY GENE EXPRESSION PROFILING
  Kohrt, H. E., Li, L., Alizadeh, A. A., Heish, S., Goldstein, M. J., Strober, S., Sarwal, M., Lowsky, R.
  ELSEVIER SCIENCE INC. 2011: S336

• Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy
  Anderson, M. W., Freud, A. G., Zhao, S., Alizadeh, A. A., Kohrt, H. E., Warnke, R., Levy, R., Natkunam, Y.
• **Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy**
  Anderson, M. W., Freud, A. G., Zhao, S., Alizadeh, A. A., Kohrt, H. E., Warnke, R., Levy, R., Natkunam, Y.
  NATURE PUBLISHING GROUP. 2011: 285A

• **Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria**
  Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., Arber, D. A.
  NATURE PUBLISHING GROUP. 2011: 328A

• **Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria**
  Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., Arber, D. A.
  NATURE PUBLISHING GROUP. 2011: 328A

• **Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia**
  Gentles, A. J., Plevritis, S. K., Majeti, R., Alizadeh, A. A.
  2010; 304 (24): 2706-2715

• **Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47**
  Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., Majeti, R., Weissman, I. L.
  2010; 2 (63)

• **NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome**
  Myklebust, J. H., Irish, J. M., Brody, J., Alizadeh, A. A., Czerwinski, D., Houot, R., Kohrt, H. E., Kolstad, A., Levy, R.
  AMER SOC HEMATOLOGY. 2010: 67–68

• **A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes**
  Pollyea, D. A., Raval, A., Kuster, B., Gotlib, J. R., Alizadeh, A. A., Mitchell, B. S.
  AMER SOC HEMATOLOGY. 2010: 788

• **Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment**
  Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R., Gascoyne, R. D., Briones, J., Tibshirani, R. J., Myklebust, et al
  AMER SOC HEMATOLOGY. 2010: 836–37

• **Noninvasive Prediction of Graft-Verus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling**
  Kohrt, H. E., Li, L., Alizadeh, A. A., Goldstein, M. J., Strober, S., Sarwal, M., Lowsky, R.
  AMER SOC HEMATOLOGY. 2010: 393–94

• **Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma**
  Layn, K., Alizadeh, A. A., Kattah, N., Levy, S., Levy, R.
  AMER SOC HEMATOLOGY. 2010: 1678–79

• **Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies**
  Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., Advani, R., Natkunam, Y., Levy, R.
  AMER SOC HEMATOLOGY. 2010: 1291–92

• **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience**
  Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.
  AMERICAN JOURNAL OF HEMATOLOGY 2010; 85 (11): 877-881

• **B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression**
  Irish, J. M., Myklebust, J. H., Alizadeh, A. A., Houot, R., Sharman, J. P., Czerwinski, D. K., Nolan, G. P., Levy, R.
Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. *Leukemia & Lymphoma* 2010; 51 (7): 1200-1216.

Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). *Leukemia Research* Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., Majeti, R., Kogel, K. E., Azar, C. A., Patel, S., Alizadeh, A. A. 2010; 34 (5): 594-597.

Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling. *10th American Transplant Congress* Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., Negri, R., Strober, S., Lowsky, R., Sarwal, M. WILEY-BLACKWELL.2010: 483–483.

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). *Blood* (e-Letter) Kohrt HE, Patel S, Ho M, Owen T, Majeti R, Gotlib JR, Coutre SE, Medeiros BC, Alizadeh AA. 2010; 113 (1): 28-36.

Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts. *51st Annual Meeting and Exposition of the American-Society-of-Hematology* Chao, M. P., Alizadeh, A. A., Tang, C. Z., Myklebust, J. H., Varghese, B., Jan, M., Levy, R., Weissman, I. L., Majeti, R. AMER SOC HEMATOLOGY.2009: 1063–64.

High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis. Logan, A. C., Su, R., George, T. I., Kohrt, H. E., Medeiros, B. C., Alizadeh, A. A. AMER SOC HEMATOLOGY.2009: 554.

Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma. *51st Annual Meeting and Exposition of the American-Society-of-Hematology* Alizadeh, A. A., Gentles, A. J., Plevritis, S. K., Levy, R. AMER SOC HEMATOLOGY.2009: 1153–53.

Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. *51st Annual Meeting and Exposition of the American-Society-of-Hematology* Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Taleja, N., Shyam, R., Natkunam, Y., Gascoyne, R. D., Briones, J., Advani, R., Lossos, I. S., Levy, et al AMER SOC HEMATOLOGY.2009: 258–58.

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). *51st Annual Meeting and Exposition of the American-Society-of-Hematology* Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib JR, Coutre S., Medeiros B. C., Alizadeh A. A. AMER SOC HEMATOLOGY.2009: 646–47.

Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. *51st Annual Meeting and Exposition of the American-Society-of-Hematology* Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., Medeiros, B. C. AMER SOC HEMATOLOGY.2009: 420–21.

A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling. *51st Annual Meeting and Exposition of the American-Society-of-Hematology* Myklebust, J. H., Irish, J. M., Houot, R., Brody, J., Czerwinski, D. K., Alizadeh, A. A., Kolstad, A., Levy, R. AMER SOC HEMATOLOGY.2009: 316–16.

Therapeutic Potential of Anti-CD137 Antibody in Lymphoma. *51st Annual Meeting and Exposition of the American-Society-of-Hematology* Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., Levy, R. AMER SOC HEMATOLOGY.2009: 301–2.

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion. *Blood* Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., Levy, R.
• CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON-HODGKIN LYMPHOMA AND A THERAPEUTIC ANTIBODY TARGET THAT SYNERGIZES WITH RITUXIMAB 38th Annual Scientific Meeting of the ISEH-Society-for-Hematology-and-Stem-Cells
Chao, M. P., Alizadeh, A., Tang, C. Z., Jan, M., Levy, R., Majeti, R., Weissman, I. L.
ELSEVIER SCIENCE INC.2009: S8–S9

• CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells CELL.
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., Weissman, I. L.
2009; 138 (2): 286-299

• A stem cell-like signature predicts histological transformation and influences survival in follicular lymphoma patients
Gentles, A., Alizadeh, A., Lee, S., Shahbaba, B., Shachaf, C., Levy, R., Koller, D., Plevritis, S.
AMER ASSOC CANCER RESEARCH.2009

• A pluripotency signature predicts histological transformation and influences survival in follicular lymphoma patients Blood
Gentles AJ**, Alizadeh AA** (contributed equally), Lee S, Myklebust JH, Shachaf CM, Shahbaba B, Levy R, Koller D, Plevritis SK.
2009

• Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clinical advances in hematology & oncology : H&O
Alizadeh, A. A., Advani, R. H.
2008; 6 (12): 899-909

• CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells 50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Weissman, I. L.
AMER SOC HEMATOLOGY.2008: 284–84

• LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. 50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium
Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., Bordes, R., Cohen, J., Horning, S., Levy, R., Lossos, I. S., Natkunam, Y.
AMER SOC HEMATOLOGY.2008: 1291–91

• Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germinal center LEUKEMIA & LYMPHOMA
Alizadeh, A. A., Lossos, I. S.
2008; 49 (3): 377-380

• Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray JOURNAL OF CLINICAL MICROBIOLOGY
Chiu, C. Y., Alizadeh, A. A., Rouskin, S., Merker, J. D., Yeh, E., Yagi, S., Schnurr, D., Patterson, B. K., Ganem, D., DeRisi, J. L.
2007; 45 (7): 2340-2343

• Cell-type specific gene expression profiles of leukocytes in human peripheral blood BMC GENOMICS
Palmer, C., Diehn, M., Alizadeh, A. A., Brown, P. O.
2006; 7

• Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas BLOOD
Lu, X. Q., Nechushtan, H., Ding, F. Y., Rosado, M. F., Singal, R., Alizadeh, A. A., Lossos, I. S.
2005; 105 (7): 2924-2932

• Distinct IL-4 intracellular signaling in germinal center B-cell like and activated B-cell-like diffuse large B-cell lymphoma: Novel opportunities for therapeutic interventions.
Lossos, I. S., Lu, X. Q., Ding, F. Y., Rosado, M., Alizadeh, A. A., Nechushtan, H.
AMER SOC HEMATOLOGY.2004: 73A-74A

• AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity LEUKEMIA
Lossos, I. S., Levy, R., Alizadeh, A. A.
2004; 18 (11): 1775-1779
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. *BLOOD*
Rosenwald, A., Chuang, E. Y., Davis, R. E., Wiestner, A., Alizadeh, A. A., Arthur, D. C., Mitchell, J. B., Marti, G. E., Fowler, D. H., Wilson, W. H., Staudt, L. M. 2004; 104 (5): 1428-1434

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. *NEW ENGLAND JOURNAL OF MEDICINE*
Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechsler, M. A., Tibshirani, R., Botstein, D., Levy, R. 2004; 350 (18): 1828-1837

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. *PLoS biology*
Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., Chi, J., van de Rijn, M., Botstein, D., Brown, P. O. 2004; 2 (2): E7-?

Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence for the existence of distinctive pathways relevant to disease
Kasperkovitz, P., Verbeet, N. L., Smeets, T., Tak, P. P., Huizinga, T., Baltus, B., Timmer, T., Pieterman, E., Fero, M., Firestein, G. S., Alizadeh, A. A., van der Pouw Kraan, T. C., Verweij, et al
BIOMED CENTRAL LTD. 2004: S25

Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds *PLOS BIOLOGY*
Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., Chi, J. T., van de Rijn, M., Botstein, D., Brown, P. O. 2004; 2 (2): 206-214

Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock *LANCET*
Pathan, N., Hemingway, C. A., Alizadeh, A. A., Stephens, A. D., Boldrick, J. C., Orazi, E. E., McCabe, C., Welch, S. B., Whitby, A., O’Gara, P., Nadel, S., Relman, D. A., Harding, et al
2004; 363 (9404): 203-209

Prediction of survival in diffuse large B-Cell lymphoma (DLBCL) based on the expression of six genes.
Lossos, I. S., Czerwinski, D., Tibshirani, R., Wechsler, M., Alizadeh, A. A., Botstein, D., Levy, R.
AMER SOC HEMATOLOGY. 2003: 391A

T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression *PLOS BIOLOGY*
Roose, J. P., Diehn, M., Tomlinson, M. G., Lin, J., Alizadeh, A. A., Botstein, D., Brown, P. O., Weiss, A. 2003; 1 (2): 271-287

T cell receptor-independent basal signaling via Erk and Ablkinases suppresses RAG gene expression. *PLoS biology*
Roose, J. P., Diehn, M., Tomlinson, M. G., Lin, J., Alizadeh, A. A., Botstein, D., Brown, P. O., Weiss, A.
2003; 1 (2): E53-?

Rheumatoid arthritis is a heterogeneous disease - Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues *ARTHRITIS AND RHEUMATISM*
Kraan, T. C., van Gaalen, F. A., Kasperkovitz, P. V., Verbeet, N. L., Smeets, T. J., Kraan, M. C., Fero, M., Tak, P. P., Huizinga, T. W., Pieterman, E., Breedveld, F. C., Alizadeh, A. A., Verweij, et al
2003; 48 (8): 2132-2145

Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations *BLOOD*
Martinez-Climent, J. A., Alizadeh, A. A., Segraves, R., Blesa, D., Rubio-Moscardo, F., Albertson, D. G., Garcia-Conde, J., Dyer, M. J., Levy, R., Pinkel, D., Lossos, I. S.
2003; 101 (8): 3109-3117

Individuality and variation in gene expression patterns in human blood *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Whitney, A. R., Diehn, M., Popper, S. J., Alizadeh, A. A., Boldrick, J. C., Relman, D. A., Brown, P. O.
2003; 100 (4): 1896-1901

HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma *BLOOD*
Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., Levy, R.
2003; 101 (2): 433-440

Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling *N Engl J Med*
Sarwal M, Chen X, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Alizadeh AA, Masek M, Diehn, M, Salvatierra O Jr, Brown PO
2003; 349 (2): 125-38

- **Comparison of molecular abnormalities in bronchial brushings and tumor touch preps: The potential use of fluorescence in situ hybridization (FISH) as a predictive marker in early stage lung carcinomas**
  Barkan, G. A., Caraway, N. P., Zaidi, T., Alizadeh, A., Johnston, D., Jiang, F., Katz, R. L.
  NATURE PUBLISHING GROUP. 2003: 59A

- **SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data**
  NUCLEIC ACIDS RESEARCH
  Diehn, M., Sherlock, G., Binkley, G., Jin, H., Matses, J. C., Hernandez-Boussard, T., Rees, C. A., Cherry, J. M., Botstein, D., Brown, P. O., Alizadeh, A. A.
  2003; 31 (1): 219-223

- **Caspase-12 expression is markedly reduced in NF-E2(-/-)megakaryocytes and caspase-12(-/-) platelets exhibit a defect in integrin alpha IIb beta 3 inside-out signaling.**
  Kerrigan, S. W., Murphy, R. P., Alizadeh, A., Diehn, M., Shattil, S. J., Leavitt, A. D.
  AMER SOC HEMATOLOGY. 2002: 13A

- **GAL is a novel IL-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.**
  Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., Levy, R.
  AMER SOC HEMATOLOGY. 2002: 90A-91A

- **Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation (vol 99, pg 11796, 2002)**
  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
  Diehn, M., Alizadeh, A. A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., Crabtree, G. R., Brown, P. O.
  2002; 99 (23): 15245

- **Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays**
  AMERICAN JOURNAL OF PATHOLOGY
  Liu, C. L., Prapong, W., Natkunam, Y., Alizadeh, A., Montgomery, K., Gilks, C. B., van de Rijn, M.
  2002; 161 (5): 1557-1565

- **Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation**
  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
  Diehn, M., Alizadeh, A. A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., Crabtree, G. R., Brown, P. O.
  2002; 99 (18): 11796-11801

- **Distinctive gene expression profiles in synovial tissue from rheumatoid arthritis patients by cDNA microarray analysis.**
  Kraan, T. C., van Gaalen, F. A., Alizadeh, A. A., Fero, M., Huizinga, T. W., Pieterman, E., Breedveld, F. C., Botstein, D., Brown, P. O., Verweij, C. L.
  WILEY. 2002: S266-S267

- **Rheumatoid arthritis is a heterogeneous disease: Discovery of distinctive gene expression profiles in rheumatoid synovia.**
  Verweij, C. L., Kraan, T. T., van Gaalen, F. A., Kasperkowitz, P. V., Smeets, T. J., Alizadeh, A. A., Tak, P. P., Huizinga, T. W., Pieterman, E., Breedveld, F. C., Botstein, D., Brown, P. O.
  WILEY. 2002: S266

- **Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes**
  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
  Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Thorstenson, Y., Oefner, P. J., Brown, P. O., Botstein, D., Levy, R.
  2002; 99 (13): 8886-8891

- **The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile**
  BLOOD
  Huang, J. Z., Sanger, W. G., Greiner, T. C., Staudt, L. M., Weisenburger, D. D., Pickering, D. L., Lynch, J. C., Armitage, J. O., Warnke, R. A., Alizadeh, A. A., Lossos, I. S., Levy, R., Chan, et al
  2002; 99 (7): 2285-2290

- **Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation**
  NUCLEIC ACIDS RESEARCH
  Yang, Y. H., Dudoit, S., Luu, P., Lin, D. M., Peng, Ngai, J., Speed, T. P.
  2002; 30 (4): e15

- **In vivo regulation of human skeletal muscle gene expression by thyroid hormone**
  GENOME RESEARCH

---

Ash A. Alizadeh, MD/PhD
http://cap.stanford.edu/profiles/Ash_Alizadeh/
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. *Proceedings of the National Academy of Sciences of the United States of America* 2002; 99 (2): 972-977

Discovery of distinctive gene expression profiles in human arthritides by cDNA micro-array analysis. *Proceedings of the National Academy of Sciences of the United States of America* 2002; 99 (2): 1639-1647

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *Biomed Central Ltd.* 2002

Higher-grade transformed follicle center lymphomas (FCL): Gene expression profiling comparison to pre-transformed FCL and to de novo diffuse large B-cell lymphomas (DLBCL). *Journal of Experimental Medicine* 2001; 195 (1): 41-52

Genetic approaches using primary megakaryocytes to identify effectors of platelet integrin signaling. *Journal of Experimental Medicine* 2001; 195 (1): 41-52

Towards a novel classification of human malignancies based on gene expression patterns. *Journal of Pathology* 2001; 195 (1): 41-52

Discovery of distinctive gene expression profiles in human arthritides by cDNA microarray analysis. *Proceedings of the National Academy of Sciences of the United States of America* 2001; 195 (1): 41-52

Genomic analysis of renal allograft dysfunction using cDNA microarrays. *18th World Congress of the Transplantation-Society* 2001; 297-98

Supervised harvesting of expression trees. *Genome Biology* 2001; 2 (1)

BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma. *Nature* 2001; 173A

BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma. *Nature* 2001; 173A

Gene expression profiling of rheumatoid synovitis using cDNA microarrays. *Proceedings of the National Academy of Sciences of the United States of America* 2000; S160

Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. *Proceedings of the National Academy of Sciences of the United States of America* 2000; S160
Exploring gene expression signatures of host responses to infection
Boldrick, J. C., Belcher, C. E., Alizadeh, A. A., Liu, C. L., Diehn, M., Brown, P. O., Relman, D. A.
OXFORD UNIV PRESS INC.2000: 218–18

Examining the living genome in health and disease with DNA microarrays JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Diehn, M., Alizadeh, A. A., Brown, P. O.
2000; 283 (17): 2298-2299

Genomic-scale gene expression profiling of normal and malignant immune cells CURRENT OPINION IN IMMUNOLOGY
Alizadeh, A. A., Staudt, L. M.
2000; 12 (2): 219-225

‘Gene shaving’ as a method for identifying distinct sets of genes with similar expression patterns. Genome biology
Hastie, T., Tibshirani, R., Eisen, M. B., Alizadeh, A., Levy, R., Staudt, L., Chan, W. C., Botstein, D., BROWN, P.
2000; 1 (2): RESEARCH0003-?

Gene expression in large B-cell lymphoma using cDNA microarray technology.
Chan, W. C., Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., Powell, J. I., Yang, L., Greiner, T. C., Weisenburger, D. D., Armitage, J. O., Marti, et al
AMER SOC HEMATOLOGY.1999: 698A–698A

Genome-wide analysis of DNA copy-number changes using cDNA microarrays NATURE GENETICS
Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov, A., Williams, C. F., Jeffrey, S. S., Botstein, D., Brown, P. O.
1999; 23 (1): 41-46

The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes 64th Symposia: Signaling and Gene Expression in the Immune System
Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., Powell, J. I., Yang, L., Marti, G. E., Moore, D. T., Hudson, J. R., Chan, W. C., Greiner, et al
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT.1999: 71–78

Probing lymphocyte biology by genomic-scale gene expression analysis JOURNAL OF CLINICAL IMMUNOLOGY
Alizadeh, A., Eisen, M., Botstein, D., Brown, P. O., Staudt, L. M.
1998; 18 (6): 373-379

DNA microarrays as ‘microscopes’ for watching a genome in action
Brown, P. O., Botstein, D., Alizadeh, A., Derisi, J., Diehn, M., Eisen, M., Iyer, Perou, C., Pollack, J., Ross, D., Spellman, P., Staudt, L.
AMER SOC CELL BIOLOGY.1998: 2A